Cue Biopharma, Inc. (CUE) Income Statement Analysis

See more : SmileDirectClub, Inc. (SDC) Income Statement Analysis – Financial Results

Complete financial analysis of Cue Biopharma, Inc. (CUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cue Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

ADAMA Ltd. (200553.SZ) Income Statement Analysis – Financial Results
Wall Financial Corporation (WFC.TO) Income Statement Analysis – Financial Results
SEBinvest – Danske Aktier Akkumulerende AKL (SEIDAAP.CO) Income Statement Analysis – Financial Results
MediNavi AG (MDQK.HM) Income Statement Analysis – Financial Results
American Transportation Holdings, Inc. (ATHI) Income Statement Analysis – Financial Results

Cue Biopharma, Inc. (CUE)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.cuebiopharma.com

About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	5.49M	1.25M	14.94M	3.15M	3.46M	1.14M	0.00	0.00	0.00
Cost of Revenue	38.10M	1.81M	-1.78M	33.55M	27.49M	28.54M	419.57K	202.09K	44.82K
Gross Profit	-32.61M	-560.83K	16.72M	-30.39M	-24.03M	-27.40M	-419.57K	-202.09K	-44.82K
Gross Profit Ratio	-593.93%	-45.04%	111.90%	-963.48%	-694.90%	-2,398.16%	0.00%	0.00%	0.00%
Research & Development	40.80M	38.58M	41.35M	33.55M	27.49M	28.54M	18.90M	5.69M	1.50M
General & Administrative	16.68M	16.17M	17.31M	14.65M	12.74M	11.30M	4.33M	1.97M	425.08K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	16.68M	16.17M	17.31M	14.65M	12.74M	11.30M	4.33M	1.97M	425.08K
Other Expenses	-37.94M	0.00	0.00	0.00	64.00K	165.34K	0.00	0.00	0.00
Operating Expenses	19.54M	54.75M	58.65M	48.20M	40.23M	39.84M	23.23M	7.66M	1.93M
Cost & Expenses	57.64M	54.75M	58.65M	48.20M	40.23M	39.84M	23.23M	7.66M	1.93M
Interest Income	2.66M	928.24K	45.90K	463.91K	419.00K	376.01K	35.00	52.00	0.00
Interest Expense	1.25M	713.82K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.44M	1.81M	-1.78M	1.06M	5.35M	760.01K	419.57K	202.09K	44.82K
EBITDA	-46.05M	-50.49M	-45.44M	-43.99M	-35.96M	-37.94M	-22.81M	-7.46M	-1.88M
EBITDA Ratio	-838.83%	-4,076.94%	-292.56%	-1,394.44%	-1,063.30%	-3,320.19%	0.00%	0.00%	0.00%
Operating Income	-52.15M	-53.22M	-43.71M	-45.04M	-36.77M	-38.70M	-23.23M	-7.66M	-1.93M
Operating Income Ratio	-949.89%	-4,274.31%	-292.56%	-1,427.96%	-1,063.30%	-3,386.71%	0.00%	0.00%	0.00%
Total Other Income/Expenses	1.42M	215.00K	45.90K	463.91K	482.79K	541.35K	35.00	52.00	0.00
Income Before Tax	-50.73M	-53.01M	-43.67M	-44.58M	-36.29M	-38.16M	-23.23M	-7.66M	-1.93M
Income Before Tax Ratio	-924.10%	-4,257.09%	-292.25%	-1,413.26%	-1,049.33%	-3,339.33%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-214.43K	495.00K	206.25K	412.00K	825.00K	0.00	0.00	0.00
Net Income	-50.73M	-52.80M	-44.16M	-44.78M	-36.70M	-38.98M	-23.23M	-7.66M	-1.93M
Net Income Ratio	-924.10%	-4,239.87%	-295.56%	-1,419.79%	-1,061.25%	-3,411.53%	0.00%	0.00%	0.00%
EPS	-1.11	-1.48	-1.41	-1.56	-1.66	-1.94	-1.13	-0.37	-0.09
EPS Diluted	-1.11	-1.48	-1.41	-1.56	-1.66	-1.94	-1.13	-0.37	-0.09
Weighted Avg Shares Out	45.75M	35.65M	31.29M	28.69M	22.04M	20.13M	20.64M	20.64M	20.64M
Weighted Avg Shares Out (Dil)	45.75M	35.65M	31.29M	28.69M	22.04M	20.13M	20.64M	20.64M	20.64M

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 29, 2024globenewswire.com

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today...

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

November 25, 2024globenewswire.com

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today...

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

November 14, 2024zacks.com

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago.

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 14, 2024globenewswire.com

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today...

Cue Biopharma Announces Strategic Organizational Transition

November 14, 2024globenewswire.com

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

November 8, 2024globenewswire.com

BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today presented...

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

October 4, 2024globenewswire.com

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster...

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

September 26, 2024globenewswire.com

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public offering of...